(NASDAQ: MESO) Mesoblast's forecast annual revenue growth rate of 172.94% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 106.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 26.17%.
Mesoblast's revenue in 2025 is $17,198,000.On average, 6 Wall Street analysts forecast MESO's revenue for 2026 to be $119,039,508,325, with the lowest MESO revenue forecast at $71,498,967,066, and the highest MESO revenue forecast at $144,751,489,178. On average, 7 Wall Street analysts forecast MESO's revenue for 2027 to be $250,860,768,980, with the lowest MESO revenue forecast at $127,945,520,013, and the highest MESO revenue forecast at $430,068,974,832.
In 2028, MESO is forecast to generate $462,221,750,569 in revenue, with the lowest revenue forecast at $225,325,423,599 and the highest revenue forecast at $840,247,259,578.